Tvardi Therapeutics, Inc. TVRD

Tvardi Therapeutics reports preclinical data supporting STAT3 inhibitors for ulcerative colitis (UC). In a chronic colitis model, oral TTI-101 achieved eightfold higher concentrations in the colon than plasma, normalized STAT3-regulated gene expression and prevented adenocarcinoma formation. Across multiple UC models, these results reinforce a three-part UC biology: immune dysregulation, inflammation and proliferation that STAT3 drives. Tvardi is advancing TTI-109, a next-generation prodrug designed to improve colon delivery and tolerability. A Phase 1 healthy volunteer study of TTI-109 showed predictable pharmacokinetics, favorable GI tolerability and modulation of UC-relevant immune cell populations, supporting planned GI trials pending IND clearance. The publication expands the evidence base for STAT3 inhibition as a therapeutic approach to UC and related colitis-associated cancer risk. Preclinical efficacy signals plus Phase 1 data support pursuing GI trials, potentially shaping near-term pipeline momentum.

Tvardi Therapeutics reported second quarter 2026 financial results and issued a business update. Quarterly results and business updates directly shape views on financial health and future prospects.

Tvardi Therapeutics, Inc. reported its Q2 earnings, highlighting key financial metrics and operational updates. The company continues to advance its pipeline, focusing on innovative therapies. Investors are keenly observing the developments as they may influence future market performance. The earnings report indicates moderate progress in financial performance and operational focus, which may influence investor sentiment but is not expected to drastically alter the company's trajectory.

Tvardi Therapeutics, Inc. reported its financial results for the second quarter of 2025, highlighting key metrics and developments in its ongoing projects. The company provided updates on its pipeline and strategic initiatives aimed at enhancing growth and market presence. Management expressed optimism about future prospects and outlined plans for upcoming milestones. The financial results and strategic updates indicate a moderate influence on the company's performance and market positioning.

Tvardi Therapeutics selects ulcerative colitis as the initial indication for TTI-109. Selection of ulcerative colitis advances Tvardi's clinical pipeline for TTI-109.

TVRD stock surges 149% this week on momentum at Tvardi Therapeutics. 149% weekly gain signals major positive shift in market perception and trajectory for Tvardi Therapeutics.

Tvardi Therapeutics reports Phase 1 results for TTI-109 confirming prodrug design, improved tolerability and pharmacodynamic evidence of STAT3 target engagement. Positive Phase 1 data on lead asset validates mechanism and supports clinical advancement.

Tvardi Therapeutics, Inc. (TVRD) announced first quarter 2026 financial results and provided a business update. Quarterly results and business updates affect financial performance and investor sentiment.

Tvardi Therapeutics announced fourth quarter and full-year 2025 financial results and provided a business update. Quarterly and annual earnings releases with business updates often signal pipeline progress and financial health, significantly influencing biotech stock trajectories and investor sentiment.

Tvardi Therapeutics, Inc. is under scrutiny for its cash burn rate as it navigates its financial landscape. Investors are particularly concerned about the sustainability of its operations given the current cash reserves and ongoing expenditures. The company is focusing on its clinical development programs, but the pace of cash consumption raises questions about its ability to fund future initiatives without additional capital. Analysts are monitoring the situation closely as it could impact investor sentiment and the company's strategic direction. The cash burn rate could moderately influence financial performance and investor confidence, but it is not expected to drastically alter the company's trajectory.

Tvardi Therapeutics, Inc. announced further data from its Phase 2 REVERT trial for idiopathic pulmonary fibrosis (IPF), revealing promising results that enhance understanding of the drug's efficacy and safety profile. The data indicates potential benefits for patients, contributing to the ongoing development of therapies for this challenging condition. The company aims to leverage these insights to advance its clinical program and improve treatment options for IPF. The new data from the Phase 2 trial could significantly influence the company's future product development and market positioning in the IPF treatment landscape.

Tvardi Therapeutics, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its ongoing developments and strategic initiatives in the healthcare sector. The conference is a key event for investors and industry leaders, providing a platform for companies to showcase their innovations and future plans. Participation in a major healthcare conference can enhance visibility and investor interest, potentially influencing market sentiment.

Tvardi Therapeutics, Inc. (TVRD) is showing signs of potential recovery, with analysts suggesting that the stock may be nearing a bottom. Factors contributing to this outlook include recent developments in the company's pipeline and market conditions that could favor a rebound. Investors are encouraged to consider buying the stock now to capitalize on the anticipated upward movement. Recent developments and market conditions indicate a significant potential for recovery and improved investor sentiment.

Tvardi Therapeutics, Inc. (TVRD) reported its financial results for the third quarter of 2025, highlighting key metrics and developments in its ongoing projects. The company provided updates on its pipeline and strategic initiatives aimed at advancing its therapeutic offerings. Management expressed optimism about future growth and potential market opportunities, emphasizing their commitment to innovation and shareholder value. Significant updates on pipeline and strategic initiatives could alter the company's trajectory and investor sentiment.

Tvardi Therapeutics, Inc. reported its Q3 earnings, highlighting key financial metrics and developments. The company continues to focus on its therapeutic pipeline, with updates on ongoing clinical trials and research initiatives. Financial results indicate a strategic positioning for future growth, despite challenges in the market. Investors are keenly observing the company's progress and potential impacts on its valuation. The earnings report reflects moderate developments that may influence financial performance and market sentiment but are not expected to drastically alter the company's trajectory.

Tvardi Therapeutics, Inc. (TVRD) is being highlighted as a strong 'buy the bottom' stock due to its promising pipeline and recent developments that suggest potential for significant growth. The company is focused on innovative therapies for serious diseases, and recent market conditions have created an attractive entry point for investors. Analysts believe that the current valuation does not reflect the company's future potential, making it a compelling investment opportunity. Recent developments and market conditions indicate a significant potential for growth and strategic moves that could alter the company's trajectory.

Tvardi Therapeutics, Inc. (TVRD) has seen a significant decline of 83.0% over the past four weeks, raising concerns among investors. However, analysts suggest that the stock may be poised for a turnaround due to potential upcoming catalysts, including advancements in their clinical trials and strategic partnerships. The company is focused on developing innovative therapies for serious diseases, which could enhance its market position. Investors are advised to monitor the situation closely as the stock may present a buying opportunity amid the downturn. Potential advancements in clinical trials and strategic partnerships could moderately influence the company's future performance.

Tvardi Therapeutics, Inc. (TVRD) experienced a dramatic 84% drop in stock value following the announcement that its Phase II study on a fibrosis treatment failed to meet key objectives. The study's disappointing results have raised concerns about the company's future prospects and ability to advance its therapeutic pipeline, leading to a significant negative reaction from investors. The failure of a Phase II study represents a critical setback that could fundamentally redefine the company's competitive position and long-term prospects.

Tvardi Therapeutics, Inc. (TVRD) experienced a significant decline of 83.3% following disappointing results from its Phase 2 trial of TTI-101 for idiopathic pulmonary fibrosis (IPF). The trial did not meet its primary endpoint, raising concerns about the drug's efficacy and the company's future prospects. Investors reacted negatively, leading to a sharp drop in stock price as the company faces challenges in advancing its pipeline. The failure of the Phase 2 trial is likely to significantly impact investor sentiment and the company's future development plans.

Tvardi Therapeutics, Inc. announced preliminary data from its Phase 2 REVERT trial, which investigates the efficacy of its treatment for Idiopathic Pulmonary Fibrosis (IPF). The results indicate promising outcomes, showing improvements in lung function and quality of life for patients. The company plans to further analyze the data and engage with regulatory authorities to discuss the next steps in development. This update highlights Tvardi's commitment to addressing unmet needs in IPF treatment. Promising trial results could significantly influence future product development and market positioning for Tvardi Therapeutics.

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has gained popularity among retail investors, who now own 57% of the company's shares, while institutional investors hold 26%. This significant retail ownership indicates strong interest and potential influence on the company's market dynamics. The high retail ownership may moderately influence market sentiment and investor behavior but is not expected to fundamentally alter the company's trajectory.

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) is positioned for growth with its innovative drug development strategies and a strong pipeline. The company is focusing on advancing its lead candidate, which targets significant unmet medical needs. Recent funding and strategic partnerships are expected to bolster its research and development efforts, enhancing its competitive edge in the biotech sector. Analysts express optimism about the company's potential to deliver on its growth plans, which could lead to increased market interest and investor confidence. Strategic partnerships and advancements in drug development are likely to significantly impact future performance and investor sentiment.

Tvardi Therapeutics, Inc. (TVRD), valued at $212 million, is a clinical-stage biotech firm developing oral drugs targeting STAT3, linked to fibrosis and certain cancers. Following its merger with Cara Therapeutics, the company has gained traction, with its lead candidate, TTI-101, in Phase 2 trials for Idiopathic Pulmonary Fibrosis (IPF) and Hepatocellular Carcinoma (HCC). The FDA has granted TTI-101 orphan drug status and Fast Track Designation for HCC. With a cash runway until late 2026, Tvardi's stock is rated a 'Strong Buy' by analysts, with a potential upside of 151% from current levels. However, the company faces risks related to clinical trials and regulatory approvals. Positive trial results could significantly enhance Tvardi's market position and investor sentiment.

Oppenheimer analyst Jay Olson highlights two stocks with significant upside potential, including Tvardi Therapeutics (TVRD), which focuses on therapies for fibrosis-driven diseases. Following its recent public debut, Tvardi is advancing TTI-101, a STAT3 inhibitor for hepatocellular carcinoma and idiopathic pulmonary fibrosis. Early clinical results are promising, with positive tolerability and target engagement observed. Olson rates TVRD as an Outperform with a $65 price target, indicating a potential 129% upside. The stock has garnered a Strong Buy consensus rating from analysts. The ongoing clinical trials and positive early results for TTI-101 could significantly impact Tvardi's market position and investor sentiment.

Tvardi Therapeutics, Inc. has completed enrollment in its Phase 2 clinical trial of TTI-101 for idiopathic pulmonary fibrosis (IPF). The REVERT IPF trial is randomized, double-blind, and placebo-controlled, focusing on safety and lung function. TTI-101 is an oral small molecule inhibitor of STAT3, which plays a critical role in fibrosis. The company anticipates topline data in Q4 2025, aiming to address the unmet need in IPF treatment, where current therapies only slow disease progression. Dr. Imran Alibhai, CEO, expressed optimism about TTI-101's potential based on preclinical results. Completion of enrollment in a Phase 2 trial for a novel treatment in a high-unmet-need area could significantly influence future performance and investor sentiment.

Tvardi Therapeutics, Inc. (TVRD) reported its financial results for the first quarter of 2025, highlighting key metrics and developments in its ongoing projects. The company provided updates on its pipeline and strategic initiatives aimed at advancing its therapeutic offerings. Management expressed optimism about future growth and the potential impact of their research efforts on patient outcomes. The financial results and updates on the pipeline indicate a moderately noticeable influence on the company's future performance and market sentiment.

Tvardi Therapeutics, Inc. (TVRD) announced its participation in the American Thoracic Society 2025 Annual Conference, where it will present its latest research findings. This presentation aims to highlight the company's advancements in therapeutic solutions for respiratory diseases, showcasing its commitment to innovation in the field. The presentation at a significant conference may enhance visibility and credibility, potentially influencing investor sentiment and market positioning.

Cara Therapeutics, Inc. announced a 1-for-3 reverse stock split of its common stock, effective April 15, 2025, in connection with its merger with Tvardi Therapeutics, Inc. Following the split, Cara's shares will trade under the new name and symbol 'Tvardi Therapeutics, Inc.' (TVRD). The reverse stock split will reduce the number of outstanding shares from approximately 4.6 million to about 1.5 million. Stockholders will receive cash payments for any fractional shares. The merger is expected to result in approximately 9.4 million total outstanding shares for the combined company. The reverse stock split and merger with Tvardi Therapeutics represent significant strategic moves that could alter the company's market position and investor sentiment.

Cara Therapeutics, Inc. announced a 1-for-12 reverse stock split effective December 30, 2024, to regain compliance with Nasdaq listing requirements. The reverse stock split may have a moderately noticeable influence on the company's financial performance and stock price.

Cara Therapeutics and Tvardi Therapeutics announce merger agreement to create a Nasdaq-listed biopharmaceutical company developing treatments targeting STAT3 for fibrosis-driven diseases. The merger agreement and potential Phase 2 clinical program results are expected to significantly impact Cara Therapeutics' future trajectory and market performance.